| Entry |
|
|---|
| Name |
Methyl salicylate;
Methyl 2-hydroxybenzoate
|
|---|
| Formula |
C8H8O3
|
|---|
| Exact mass |
152.0473
|
|---|
| Mol weight |
152.1473
|
|---|
| Structure |
|
|---|
| Remark |
|
|---|
| Reaction |
|
|---|
| Pathway |
| map01061 | Biosynthesis of phenylpropanoids |
|
|---|
| Enzyme |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
26 Epidermides
264 Analgesics, anti-itchings, astringents, anti-inflammatory agents
2641 Methyl salicylic acids
D01087 Methyl salicylate (JP18/NF)
Classification of Japanese OTC drugs [BR:br08313]
Agents for respiratory organs
27 Gargles
D01087 Methyl salicylate (JP18/NF)
Agents for integumentary system
57 Analgesic, antipruritic, astringent, and anti-inflammatory remedies (incl. gel patches)
D01087 Methyl salicylate (JP18/NF)
Risk category of Japanese OTC drugs [BR:br08312]
Third-class OTC drugs
Inorganic and organic chemicals
Methyl salicylate
D01087 Methyl salicylate (JP18/NF)
Animal drugs in Japan [BR:br08331]
95 Agents for external use
953 Analgesics, anti-itchings, astringents and antiinflammatory agents
9531 Methyl salicylate and preparations
C12305 Methyl salicylate
Drug groups [BR:br08330]
Anti-inflammatory
DG01504 Nonsteroidal anti-inflammatory drug (NSAID)
DG01909 Anti-inflammatory drug, salicylic acid derivatives
D01087 Methyl salicylate
Drug classes [BR:br08332]
Anti-inflammatory
DG01504 Nonsteroidal anti-inflammatory drug (NSAID)
D01087 Methyl salicylate
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01087 Methyl salicylate
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 11
1 C8x C 23.8644 -20.8025
2 C8x C 25.0757 -21.5020
3 C8x C 26.2815 -20.8055
4 C8y C 26.2831 -19.4098
5 C8y C 25.0791 -18.7104
6 C8x C 23.8662 -19.4069
7 C7a C 25.0809 -17.3119
8 O7a O 26.2891 -16.6067
9 O6a O 23.8670 -16.6038
10 O1a O 27.5086 -18.7053
11 C1a C 27.5135 -17.3061
BOND 11
1 5 6 2
2 6 1 1
3 5 7 1
4 1 2 2
5 7 8 1
6 2 3 1
7 7 9 2
8 3 4 2
9 4 5 1
10 4 10 1
11 8 11 1
|
|---|
